ClinicalTrials.gg
CompletedNCT05451212Updated Nov 10, 2025

Open-label Study to Evaluate the Safety of Various Dosing Regimens of MuSK-CAART for MuSK Myasthenia Gravis

A Phase 1 interventional study of MuSK-CAART in MuSK Myasthenia Gravis, sponsored by Cabaletta Bio. Completed at 5 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-11-10.

Sponsored by Cabaletta Bio · Phase 1, Interventional, and Treatment

How we know

From the registry’s dates

  • Primary completion was Jul 2025, 1 year 3 months ago, and no results have been posted to the registry.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
7
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 144 studies in Myasthenia Gravis with a site in United States — 53 open to participants now, 72 under way, 24 of them phase 3. Myasthenia Gravis · United States.

Enrollment
102nd of 108
7 · median 56
Started
2022
with 9 others
Phase 1
11 of 144
3 open now
Registered
76th of 144
by date

Among the 144 studies in Myasthenia Gravis with a site in United States, this one is the 102nd largest by enrollment of the 108 interventional ones that give a count, is one of 10 that started in 2022, is one of 11 in phase 1, and was the 76th registered.

Myasthenia Gravis

331 studies on the registry are indexed under Myasthenia Gravis; 145 are open to participants now.

Browse Myasthenia Gravis studies →

Open to participants now

53 of the 144 studies in Myasthenia Gravis with a site in United States are open now. Recruiting first, the newest first:

48 more — sign in →

All 53 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 104 Myasthenia Gravis studies recruiting now, 64 (62%) set no upper age limit and 23 (22%) stop at 75 or younger; 16 take children under 18; 13 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 144 studies in Myasthenia Gravis with a site in United States, or all of them as a file.
02

Study summary

Muscle-specific tyrosine kinase (MuSK) myasthenia gravis (MG) is a rare but potentially severe disease, in which patients develop pathogenic autoantibodies that specifically target the MuSK protein in the neuromuscular junction. This phase 1 study is being conducted to evaluate the safety of various dosing regimens of an investigational cell therapy, MuSK-CAART, that can be given to patients with anti-MuSK antibody positive Myasthenia Gravis (MuSK MG), who have active disease. Various dosing regimens of MuSK-CAART alone, in combination with cyclophosphamide (CY), and in combination with CY and fludarabine (FLU) will be evaluated. Treatment with MuSK-CAART may potentially lead to complete and durable remission of disease.

03

Conditions studied

  • MuSK Myasthenia Gravis

Keywords

  • CAAR-T (Chimeric Autoantibody Receptor T Cells) Therapy
  • CAR-T (Chimeric Antigen Receptor T Cells) Therapy
  • Cell Therapy
  • Autoimmune Disease
  • Autoimmunity
  • Immunotherapy, Adoptive
  • Immune System Diseases
  • Myasthenia Gravis (MG)
  • Muscle-specific tyrosine kinase (MuSK)
  • Muscle Weakness
  • Neuromuscular Diseases
  • Musculoskeletal Diseases
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Confirmed diagnosis of MuSK-type MG with at least 1 prior positive anti-MuSK antibody test.
  • History of a negative anti-AChR (acetylcholine receptor) antibody test.
  • Positive anti-MuSK antibody test at screening
  • MG severity Class I to IVa on the MGFA (Myasthenia Gravis Foundation of America) Clinical Classification

Exclusion criteria

Exclusion Criteria:

  • Rituximab in the last 12 months.
  • Prednisone > 0.25mg/kg/day [in Part A]
  • Other disorder requiring therapies.
  • treatment for MG in the past 12 weeks.
  • Absolute lymphocyte count \< 500/µL at screening.
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
7 participants (actual)

Study arms

  • Experimental
    MuSK-CAART

    Cohort A: Infusion of MuSK-CAART at various dose levels with or without pre-treatment (6 groups planned). Cohort B: Infusion of MuSK-CAART at the dose regimen selected from Part A.

    Biological: MuSK-CAART

Interventions

  • BiologicalMuSK-CAART

    Intravenous infusion of MuSK-CAART at different doses. Subjects may also receive MuSK-CAART following pre-treatment with CY, or CY plus FLU.

06

What researchers measure

Primary outcomes

  1. Adverse events

    Incidence of adverse events (AEs), including dose-limiting toxicities (DLTs) and AEs that are related to MuSK-CAART.

    Time frame: 3 months

Secondary outcomes

  1. Total MuSK-CAART positive cells

    Total MuSK-CAART positive cells for each manufacturing run.

    Time frame: Baseline

  2. Percent of CAAR-transduced cells

    Percent of total cells for infusion that are CAAR (Chimeric Autoantibody Receptor)-transduced cells.

    Time frame: Baseline

  3. Cellular kinetics profile of MuSK-CAART

    Cellular kinetics profile of MuSK-CAART after infusion.

    Time frame: Up to 36 months

  4. Change in MuSK autoantibody titer

    Change in MuSK autoantibody titer compared to pre-infusion visit by clinically validated assay.

    Time frame: Up to 36 months

Other outcomes

  1. Use of Concomitant Therapies

    Frequency and dose of concomitant therapies.

    Time frame: Up to 36 months

  2. Measurement of Clinical Symptoms using MG-ADL

    Measurement of clinical symptoms using the Myasthenia Gravis Activities of Daily Living (MG-ADL) assessment.

    Time frame: Up to 36 months

  3. Measurement of Clinical Symptoms using QMG

    Measurement of clinical symptoms using the Quantitative Myasthenia Gravis (QMG) assessment.

    Time frame: Up to 36 months

  4. Measurement of Clinical Symptoms using MGC

    Measurement of clinical symptoms using the Myasthenia Gravis Composite (MGC) assessment.

    Time frame: Up to 36 months

  5. Measurement of Quality of Life (QoL) using MG-QOL-15r

    Measurement of Quality of Life using the MG-QOL-15r (Myasthenia Gravis Qualify of Life 15-item scale, revised) questionnaire.

    Time frame: Up to 36 months

07

Study locations

5 sites
  • UC Irvine, Department of Neurology
    Orange, California 92868, United States
  • UC Davis, Department of Neurology
    Sacramento, California 95817, United States
  • University of Kansas Medical Center
    Kansas City, Kansas 66160, United States
  • Oregon Health & Science University (OHSU)
    Portland, Oregon 97239, United States
  • Houston Methodist Hospital
    Houston, Texas 77030, United States
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Nov 2022 to primary completion in Jul 2025, 32 months.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 30, 2022
First posted
Jul 11, 2022
StartActual
Nov 23, 2022
Primary completionActual
Jul 24, 2025
CompletionActual
Jul 24, 2025
Last update
Nov 10, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Nov 10, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT05451212
Lead sponsor
Cabaletta Bio
Responsible party
Sponsor
First posted
Jul 11, 2022
Start date
Nov 23, 2022
Primary completion
Jul 24, 2025
Completion
Jul 24, 2025
Last update
Nov 10, 2025

Study contacts

Medical Director
study chair · Cabaletta Bio

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Nov 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion